The approval of Apidra SoloSTAR follows the approval and launch of Lantus SoloSTAR (insulin glargine (rDNA origin) injection) in 2007. Apidra SoloSTAR is expected to be available in pharmacies in 2009.
Angela Moskow, vice president of metabolism marketing for US at Sanofi-Aventis, said: “Patients with diabetes have to contend with the challenges of carbohydrate counting, regular blood sugar monitoring and careful administration of their insulin. Apidra SoloSTAR represents another innovation introduced by Sanofi-Aventis that offers patients a convenient option for administering their Apidra.”